Effects of Yiqi Fumai injection combined with Sacubitril/Valsartan in treatment of patients with chronic heart failure
Objective:To observe effects of Yiqi Fumai injection combined with Sacubitril/Valsartan in treatment of patients with chronic heart failure(CHF).Methods:The clinical data of 86 patients with CHF admitted to this hospital from May 2021 to May 2023 were retrospectively analyzed.According to different treatment methods,they were divided into observation group and control group,43 cases in each group.The control group was treated with Sacubitril/Valsartan sodium tablets orally,while the observation group was treated with Yiqi Fumai injection on the basis of that of the control group.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)]and serum biochemical indexes[N-terminal pro-brain natriuretic peptide(NT-proBNP),tumor necrosis factor-α(TNF-α)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.02%(40/43),which was significantly higher than 72.09%(31/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LVEDD,LVESD,NT-proBNP and TNF-α in the observation group were lower than those in the control group,the level of LVEF was higher than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Yiqi Fumai injection combined with Sacubitril/Valsartan is effective in the treatment of the CHF patients,which can effectively improve the cardiac function,inhibit the secretion of inflammatory factors and reduce the degree of myocardial injury.Moreover,it is superior to simple Sacubitril/Valsartan treatment.
NETL
NSTL
万方数据
